Steris Healthcare, a Mumbai-headquartered pharmaceutical leader with operations in Navi Mumbai, has announced a strategic expansion into South India with the establishment of a state-of-the-art distribution center in Kerala. This move underscores the company’s commitment to strengthening its national footprint and enhancing access to innovative, affordable healthcare solutions across India.
Having recently crossed the milestone of ₹100 crore in annual sales, Steris Healthcare is poised to extend its reach into Kerala, a key market with growing demand for high-quality pharmaceutical products. The new distribution center will streamline supply chain operations, ensuring faster and more efficient delivery of medicines and healthcare products to hospitals, pharmacies, and patients in the region.
Commenting on the expansion, Mr. Jeevan Kasara, Director & CEO of Steris Healthcare, said, “Our entry into Kerala marks a significant step in Steris Healthcare’s journey to becoming a pan-India healthcare solutions provider. South India represents a dynamic and rapidly growing market, and this new distribution center will allow us to serve our customers and partners with greater efficiency. We remain committed to delivering cutting-edge, affordable healthcare products that improve patient outcomes.”
Ms. Renuka Kasara, Director of Steris Healthcare, added, “Kerala’s robust healthcare infrastructure and progressive policies make it an ideal location for our expansion. By establishing a strong presence here, we aim to bridge gaps in healthcare accessibility while supporting local medical communities. This initiative aligns with our vision of making quality healthcare available to all.”
The new distribution center will create significant employment opportunities in Kerala, further contributing to the region’s economic growth while fostering stronger collaborations with local healthcare providers, distributors, and pharmacies.
Steris Healthcare’s expansion into Kerala reflects its dedication to innovation, affordability, and customer-centric growth. With a diverse portfolio spanning critical therapeutic segments, the company continues to build trust among healthcare professionals and patients nationwide.
